

# Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/AFC23A1DAACEN.html>

Date: December 2019

Pages: 2792

Price: US\$ 2,500.00 (Single User License)

ID: AFC23A1DAACEN

## Abstracts

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.

Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive

pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 131, 123, 2, 8, 219, 34 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 16, 18, 3, 1, 43 and 27 molecules, respectively.

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).

The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics

Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics

Assessment

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved  
in Therapeutics Development

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued  
Products

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product

Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ABL Bio Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics SA, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advanced BioDesign, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios

Pharmaceuticals Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AI Therapeutics, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aleta Biotherapeutics Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AlfaSigma SpA, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Allogene Therapeutics Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amphivena Therapeutics Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amplia Therapeutics Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ANP Technologies Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AnyGen Co Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea Therapeutics AB, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AptaBio Therapeutics Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aravive Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arcellx Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Argenx SE, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arrien Pharmaceuticals LLC, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arvinas Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascentage Pharma Group International, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ATP Biopharm, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AUM Biosciences Pte Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Auransa Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Oncology Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avidin Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by



AVROBIO Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avvinity Therapeutics Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bantam Pharmaceutical LLC, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma SA, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beam Therapeutics Inc, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beijing Immunochina Medical Science & Technology Co Ltd, H2 2019

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

### COMPANIES MENTIONED

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl

AB Science SA

AbbVie Inc

ABL Bio Inc

Actinium Pharmaceuticals Inc

ADC Therapeutics SA

Adlai Nortye Biopharma Co Ltd

Advanced BioDesign

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Affichem SA

Agios Pharmaceuticals Inc

AI Therapeutics

Aileron Therapeutics Inc

AIMM Therapeutics BV

Aleta Biotherapeutics Inc

AlfaSigma SpA

Allogene Therapeutics Inc

Amgen Inc

Amphivena Therapeutics Inc  
Amplia Therapeutics Ltd  
Angiocrine Bioscience Inc  
Anhui Anke Biotechnology (Group) Co Ltd  
ANP Technologies Inc  
Antisense Therapeutics Ltd  
AnyGen Co Ltd  
APIM Therapeutics AS  
Aprea Therapeutics AB  
AptaBio Therapeutics Inc  
Aptevo Therapeutics Inc  
Aptose Biosciences Inc  
Aravive Inc  
Arcellx Inc  
Argenx SE  
Arog Pharmaceuticals Inc  
Arrien Pharmaceuticals LLC  
Arvinas Inc  
Ascentage Pharma Group International  
Aslan Pharmaceuticals Ltd  
Astellas Pharma Inc  
Astex Pharmaceuticals Inc  
AstraZeneca Plc  
Atara Biotherapeutics Inc  
Athenex Inc  
ATP Biopharm  
AUM Biosciences Pte Ltd  
Auransa Inc  
Aurigene Discovery Technologies Ltd  
AVEO Oncology Inc  
Avidin Ltd  
AVROBIO Inc  
Avvinity Therapeutics Ltd  
Bantam Pharmaceutical LLC  
Bayer AG  
BCI Pharma SA  
Beam Therapeutics Inc  
Beijing Immunochina Medical Science & Technology Co Ltd  
Bellicum Pharmaceuticals Inc

BerGenBio ASA  
Betta Pharmaceuticals Co Ltd  
Bio-Cancer Treatment International Ltd  
Bio-Path Holdings Inc  
Biokine Therapeutics Ltd  
BioLineRx Ltd  
BioMed Valley Discoveries Inc  
Bionetix Inc  
Bionomics Ltd  
BioSight Ltd  
BioTheryX Inc  
BioXcel Therapeutics Inc  
BiVictriX Therapeutics Ltd  
bluebird bio Inc  
Blueprint Medicines Corp  
Boehringer Ingelheim International GmbH  
Boryung ViGenCell Inc  
Boston Biomedical Inc  
BoYen Therapeutics Inc  
Bristol-Myers Squibb Co  
Canqura Oncology AB  
Cantargia AB  
Carrick Therapeutics UK Ltd  
Catalent Inc  
Celgene Corp  
CellCentric Ltd  
Cellestis SA  
Cellerant Therapeutics Inc  
Cellipse SAS  
Cellular Biomedicine Group Inc  
Celularity Inc  
Celyad SA  
Centrose LLC  
Changzhou Qianhong Bio-Pharma Co Ltd  
CharlestonPharma LLC  
Checkpoint Therapeutics Inc  
Chimerix Inc  
Chordia Therapeutics Inc  
Chugai Pharmaceutical Co Ltd

Clear Creek Bio Inc  
Cleave Therapeutics Inc  
Constellation Pharmaceuticals Inc  
ConverGene LLC  
CRISPR Therapeutics AG  
CrystalGenomics Inc  
CSPC Pharmaceutical Group Ltd  
CuronBiotech Inc  
Cyclacel Pharmaceuticals Inc  
Daiichi Sankyo Co Ltd  
Dalriada Therapeutics Inc  
DC Prime BV  
Deciphera Pharmaceuticals Inc  
Delta-Fly Pharma Inc  
Demuris Ltd  
Denovo Biopharma LLC  
DiNonA Inc  
Dong-A ST Co Ltd  
Eli Lilly and Co  
Emercell SAS  
Eminent Biosciences  
EntreChem SL  
Epigene Therapeutics Inc  
Epizyme Inc  
Escend Pharmaceuticals Inc  
ExCellThera Inc  
Exelixis Inc  
Exonate Ltd  
F. Hoffmann-La Roche Ltd  
Fate Therapeutics Inc  
Flavocure Biotech LLC  
Forma Therapeutics Inc  
Formula Pharmaceuticals Inc  
Fortress Biotech Inc  
Forty Seven Inc  
Fujifilm Holdings Corp  
Gadeta BV  
Gamida Cell Ltd  
GC Pharma

GEMoAB Monoclonals GmbH  
Genentech Inc  
Genosco Inc  
Genus Oncology LLC  
Geron Corp  
GlaxoSmithKline Plc  
GlycoMimetics Inc  
Glycostem Therapeutics BV  
GO Therapeutics Inc  
Golden Biotechnology Corp  
GT Biopharma Inc  
H3 Biomedicine Inc  
Hanmi Pharmaceuticals Co Ltd  
Hebei Senlang Biotechnology Inc Ltd  
HEC Pharm Co Ltd  
Hefei Cosource Pharmaceutical Inc  
Helocyte Biosciences Inc  
HemoGenyx LLC  
HighPass Bio Inc  
Hinova Pharmaceuticals Inc  
Hoverink Biotechnologies Inc  
HRAIN Biotechnology Co Ltd  
Hummingbird Bioscience Pte Ltd  
Hybrigenics SA  
I-Mab Biopharma Co Ltd  
iCell Gene Therapeutics LLC  
IGF Oncology LLC  
IGM Biosciences Inc  
Imago BioSciences Inc  
Immune Onc Therapeutics Inc  
Immune System Key Ltd  
ImmunoGen Inc  
Immunomedics Inc  
Inatherys  
Incuron LLC  
Incysus Therapeutics Inc  
Incyte Corp  
Inflection Biosciences Ltd  
Inmune Bio Inc

Innovation Pharmaceuticals Inc  
Intellia Therapeutics Inc  
Interprotein Corp  
Intra-Immug Pvt Ltd  
Io Therapeutics Inc  
Iovance Biotherapeutics Inc  
Iterion Therapeutics  
Jay Pharma Inc  
Jazz Pharmaceuticals Plc  
Jeil Pharmaceutical Co Ltd  
Jiangsu Hengrui Medicine Co Ltd  
Johnson & Johnson  
JSK Therapeutics Inc  
Jubilant Biosys Ltd  
Juno Therapeutics Inc  
Juventas Cell Therapy Ltd  
JW Pharmaceutical Corp  
Kainos Medicine Inc  
Kartos Therapeutics Inc  
Karyopharm Therapeutics Inc  
Keystone Nano Inc  
Kiadis Pharma NV  
KinaRx LLC  
KisoJi Biotechnology Inc  
Komipharm International Co Ltd  
Konruns Pharmaceutical Co Ltd  
Kura Oncology Inc  
Kymera Therapeutics LLC  
Laekna Therapeutics Shanghai Co Ltd  
Lai Corporation Pty Ltd  
Lead Discovery Center GmbH  
Les Laboratoires Servier SAS  
Leukos Biotech SL  
Lineage Cell Therapeutics Inc  
Machavert Pharmaceuticals LLC  
MacroGenics Inc  
Magenta Therapeutics Inc  
Mana Therapeutics Inc  
Marker Therapeutics Inc

Mateon Therapeutics Inc  
MaxCyte Inc  
Maxinovel Pharmaceuticals  
MedAbome Inc  
MediGene AG  
Medivir AB  
MEI Pharma Inc  
Merck & Co Inc  
Merck KGaA  
Merus NV  
Meryx Inc  
Millennium Pharmaceuticals Inc  
Minneamrita Therapeutics LLC  
Miragen Therapeutics Inc  
MiRx Pharmaceuticals LLC  
Molecular Templates Inc  
Molecules For Health Inc  
Moleculin Biotech LLC  
MolMed SpA  
Mustang Bio Inc  
MyeloRx LLC  
Nanjing Legend Biotech Co Ltd  
Nanjing Sanhome Pharmaceutical Co Ltd  
Novovent Pharmaceuticals Inc  
NantKwest Inc  
Nemucore Medical Innovations Inc  
Newave Pharmaceutical Inc  
NewLink Genetics Corp  
NexImmune Inc  
Nkarta Inc  
NMS Group SpA  
Nohla Therapeutics Inc  
Northlake International LLC  
Novartis AG  
OHM Oncology  
Omeros Corp  
Oncoceutics Inc



## I would like to order

Product name: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/AFC23A1DAACEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AFC23A1DAACEN.html>